Computational Pathology Market Size, Share & Trends Analysis Report By Component (Software, Services) By Application, By Technology (Natural Language Processing Models), By End-use (Hospitals & Diagnostic Labs), By Region, And Segment Forecasts, 2025 - 2030

Computational Pathology Market Trends

The global computational pathology market size was estimated at USD 655.8 million in 2024 and is expected to grow at a CAGR of 8.24% from 2025 to 2030. The growth is attributed to the rising integration of machine learning and artificial intelligence (AI) technologies, the increasing demand for advanced solutions for faster diagnosis, the rising prevalence of chronic diseases, and increasing investment in healthcare supported by market players focused on developing advanced solutions. Moreover, the increasing focus on drug discovery and rising adoption of telepathology further contributes to the market growth.

The incorporation of machine learning and AI technologies into pathology workflows significantly transforms the diagnostic process. For instance, in October 2021, Tribun Health launched CaloPix 5, an advanced AI-powered computational pathology solution designed for diagnostics, prognosis, and drug development. This next-generation version enhances the existing image management system with features such as a fully web-based interface, high-volume storage management, and AI automation algorithms focused on breast, digestive, and lung cancer. The platform integrates various modules, including tele-learning and structured reporting, to support pathologists and laboratories in their digital transformation.

The development of such solutions enables the rapid and accurate analysis of images, allowing pathologists to identify patterns that may indicate disease progression. By automating routine tasks, AI enables pathologists to focus on more complex diagnostic challenges, thereby improving efficiency and accuracy. This shift enhances diagnostic precision and supports the development of personalized medicine through predictive modeling.

Furthermore, the increasing adoption and development of telepathology solutions are further contributing to the market growth. Telepathology allows pathologists to review cases and collaborate with colleagues across geographical boundaries, thereby enhancing accessibility and enhancing the diagnostic process. The expansion of these services has been further accelerated by the COVID-19 pandemic, which highlighted the need for remote healthcare solutions.

As healthcare organizations continue to adopt telepathology to optimize resource utilization and improve patient care, this trend is expected to significantly contribute to the market growth. In June 2023, Zomedica Corp. announced the launch of its revolutionary TRUVIEW platform, a groundbreaking diagnostic solution for the veterinary market. The telepathology and digital imaging components of this TRUVIEW platform and the company’s myZomedica web portal allow sending images to Zomedica pathologists for review and consultation. The development of such solutions has further increased the adoption of telepathology, thereby contributing to market growth.

Case Study & Insights:

Case Study: Artificial intelligence–assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsies

• This study evaluated how artificial intelligence (Paige Prostate) can improve the diagnostic accuracy and efficiency of pathologists when interpreting prostate core needle biopsy.

• As per the results, AI assistance improved diagnostic accuracy, reduced turnaround time, and enhanced efficiency, helping pathologists make faster and more consistent decisions.

Market Concentration & Characteristics

The market is experiencing a high degree of innovation driven by several interrelated advancements such as Machine Learning (ML), Deep Learning, Natural Language Processing (NLP) models, and Computer Vision. The adoption of ML algorithms has enabled pathologists to enhance diagnostic accuracy through predictive analytics as these algorithms analyze vast datasets to identify patterns that may be overlooked by human eyes, thereby facilitating earlier and more precise cancer detection. This transition to automated systems has significantly reduced the time required for diagnosis, improving workflow efficiency in clinical settings.

The level of M&A activities is moderate in the market. Mature players are acquiring emerging players to strengthen their position. For instance, in March 2023, Clarapath acquired Crosscope, a digital pathology company specializing in artificial intelligence software. Clarapath, known for its fully automated SectionStar tissue sectioning system, aims to integrate these technologies with Crosscope’s computational pathology tools to create a comprehensive platform that enhances patient-centric care in both human and animal health.

Increasing government support in the form of approvals is encouraging companies to invest in technological advancements and expansion strategies. For instance, in September 2021, Paige received the FDA de novo marketing authorization for its AI-based diagnostic software, Paige Prostate, designed for prostate cancer detection. This groundbreaking approval allows Paige Prostate to be used as an in vitro diagnostic tool via the FullFocus digital pathology viewer.

The geographical expansion is driven the growth by enhancing access to advanced solutions in various geographical locations globally. For instance, in April 2022, Crosscope Inc. partnered with Waleed Pharmacy & Stores LLC to introduce AI-enabled digital pathology solutions in Oman. This collaboration aims to enhance cancer diagnostics and care in response to the rising cancer incidence in the region. Waleed Pharmacy will represent Crosscope in Oman, leveraging its expertise to advance healthcare IT solutions.

Component Insights

Software segment dominated the market and held the largest market share of 66.5% in 2024 owing to its positive impact on clinical workflows and diagnostic processes. AI-driven software solutions significantly enhance the efficiency of pathologists by automating time-consuming tasks such as image analysis, data extraction, and report generation. Moreover, the development of advanced software allowing the adoption of computation pathology is further contributing to the segment growth. In March 2023, Aiosyn launched AiosynQC, an AI-powered automated quality control solution designed to enhance digital pathology workflows in research, diagnostics, and pharmaceuticals. This product represents the first in Aiosyn's suite of workflow solutions, aiming to facilitate the integration of computational pathology algorithms into standard practices, thereby enhancing diagnostic precision and quality.

Services segment is expected to witness the fastest growth over the forecast period owing to the increasing demand for remote services and telepathology solutions. The outsourcing of computational pathology tasks is becoming a trend driven by the need for cost-effective and scalable solutions. As healthcare institutions face challenges such as a shortage of trained pathologists, they are turning to service providers that offer specialized expertise and advanced technologies, thereby contributing to the segment growth.

Application Insights

Disease diagnosis segment dominated the market with a revenue share of 45.7% in 2024 owing to the increasing demand for accurate and efficient diagnostic tools in clinical settings. As healthcare systems face the challenges such as rising prevalence chronic conditions, there is an increasing need for advanced diagnostic tools that can enhance patient care. Companies are increasingly investing in advanced solutions to improve the diagnostics and treatment of chronic diseases. For instance, in May 2024, Microsoft collaborated with the University of Washington, and the Providence health network to address key barriers related to the widespread adoption of artificial intelligence in cancer diagnostics through an ambitious digital pathology initiative. It aims to develop a machine learning model trained on one of the largest datasets of real-world, whole-slide tissue images to enhance diagnostic accuracy and scalability in clinical settings. As hospitals and laboratories increasingly adopt digital pathology solutions, the disease diagnosis segment is expected to witness significant growth over the forecast period.

Academic research segment is expected to witness the fastest growth owing to the increasing emphasis on precision medicine and personalized healthcare, which drives the demand for advanced analytical techniques for understanding complex biological data. Academic institutions are driving innovation through research initiatives that leverage computational pathology tools to analyze large datasets.

Technology Insights

Machine learning accounted for the largest revenue share in 2024 as these technologies help enhance diagnostic accuracy and efficiency through advanced data analysis. For instance, in March 2024, Bayer and Aignostics collaborated to advance precision oncology through the development of next-generation diagnostic solutions. Furthermore, the partnership will focus on creating computational pathology algorithms driven by artificial intelligence (AI) and machine learning (ML). These algorithms will link baseline pathology data, including molecular tumor profiles, with clinical information such as patient outcomes. This integration aims to enhance patient identification, stratification, and selection for clinical trials. Such strategic efforts for the development of ML-based solutions are further contributing to segment growth.

Natural Language Processing (NLP) models’ segment is expected to witness the fastest growth driven by their ability to enhance diagnostic accuracy and streamline workflows. The integration of NLP allows for the effective analysis of unstructured medical data, such as pathology reports. This capability helps pathologists gather relevant information from vast datasets, improving the speed and precision of diagnoses.

End-use Insights

Hospitals and diagnostic labs held the largest revenue share in 2024. This can be attributed to increased adoption of digital pathology in these facilities to enhance diagnostic accuracy and streamline workflows, which is essential in managing the rising prevalence of chronic diseases such as cancer. For instance, in March 2025, Paris Saint-Joseph Hospital and Marie Lannelongue Hospital partnered with Koninklijke Philips N.V. to adopt digital pathology as part of their broader enterprise imaging strategy. This integration aims to provide healthcare professionals with seamless access to diagnostic insights spanning anatomical, cellular, and molecular data. In addition, the increasing adoption of telepathology allows these institutions to extend their reach beyond geographical limitations, making expert analyses accessible even in remote areas.

Biotechnology and pharmaceutical companies are expected to witness the fastest growth over the forecast period. These companies are leveraging advanced computational techniques to enhance drug discovery and development processes. By integrating AI and ML algorithms into workflows, they can analyze vast amounts of data more efficiently, leading to faster identification of biomarkers and therapeutic targets. Additionally, the rising demand for personalized medicine necessitates precise diagnostic tools, enabling personalized treatment plans based on individual patient needs.

Regional Insights

North America dominated the computational pathology market and accounted for the largest revenue share of 40.5% in 2024. This can be attributed to the developed healthcare infrastructure, acceptance of advanced technologies, and presence of several market players, which increases the accessibility of computational pathology solutions. The developed healthcare infrastructure of the region creates growth opportunities for the companies, thereby increasing their focus on region’s healthcare sector.

For instance, in February 2023, Clarapath acquired Crosscope to integrate tissue processing robotics with AI-powered digital pathology, aiming to revolutionize laboratory operations. This acquisition combines Clarapath's SectionStar, a fully automated tissue sectioning system, with Crosscope's advanced workflow and computational pathology tools. The collaboration seeks to address critical challenges in labs, such as labor shortages and increasing sample volumes, by enhancing efficiency and quality of care.

U.S. Computational Pathology Market Trends

Computational pathology market in the U.S. accounted for the largest share in 2024. One of the key factors driving the market growth is the high adoption rate of these solutions in the country, owing to their wide range of applications, from disease diagnosis to academic research. Moreover, the increasing efforts and investments in research to further enhance the application of computational pathology are further driving the market growth. For instance, in April 2024, the University of Pittsburgh and UPMC launched the computational pathology and AI Center of Excellence (CPACE) at the UPMC Cancer Pavilion, which aims to unite experts in these solutions and artificial intelligence to foster collaboration and innovation in medical research. CPACE focuses on utilizing AI to enhance disease detection and personalized treatment plans, ultimately improving patient care and outcomes.

Europe Computational Pathology Market Trends

The Europe computational pathology market is experiencing growth driven by the rising adoption of AI-powered diagnostic tools, increased healthcare digitization, and a focus on precision medicine. For instance, the European Union's support for AI research through initiatives like the Horizon 2020 program accelerates innovation in computational pathology. In addition, the demand for efficient, scalable diagnostic solutions, especially post-COVID-19, has further propelled the market's expansion across Europe.

Asia Pacific Computational Pathology Market Trends

Computational pathology market in Asia Pacific is expected to register the fastest growth rate over the forecast period. The region has seen a rise in the incidence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. According to the Global Cancer Observatory (GLOBOCAN 2022), around 9,826,539 people were diagnosed with cancer in 2022, with lung, breast, and colorectum cancer being the leading cancer types. This has led to a growing demand for efficient diagnostic tools and increased adoption of these solutions for disease detection, grading, and research. Moreover, the increasing investments and increasing awareness about the advantages of technologically advanced solutions are further contributing to the market growth.

Computational pathology market in China is driven by the increasing investment in healthcare infrastructure, which has led to the establishment of advanced laboratories and research facilities equipped with digital pathology technologies. The researchers are further investing in research to develop advanced solutions. For instance, researchers from the Chinese University of Hong Kong introduced a new framework, MAGA-GLTrans, in April 2025 to address the efficiency challenges in digital pathology caused by the reliance on high-magnification whole-slide imaging. It uses low-magnification images and a self-supervised magnification alignment mechanism to reduce computational time (by up to 10.7x) and storage/transfer needs (by over 20x) without compromising diagnostic accuracy. This advancement enhances the clinical utility of computational pathology, especially in time-sensitive environments like intraoperative diagnosis.

Computational pathology market in India is expected to witness significant growth over the forecast period owing to the increasing advancement in diagnostic tools that can enhance accuracy and efficiency in pathology. According to the Indian Council of Medical Research (ICMR) report, around 1,461,427 people were diagnosed with cancer in India in 2022, with incident rate of around 100.4 per 100,000 population. Moreover, the increasing awareness about advantages of these solutions is further contributing to the market growth.

Latin America Computational Pathology Market Trends

Computational pathology market in Latin America is driven by the demand for advanced diagnostic tools, particularly in oncology. In addition, technological advancements and supportive government initiatives are accelerating the integration of AI and machine learning in pathology, enhancing diagnostic accuracy and efficiency.

Middle East & Africa Computational Pathology Market Trends

Computational pathology market in MEA is driven by the increasing healthcare digitization, rising adoption of AI-driven diagnostic tools, and expanding healthcare infrastructure. Government initiatives to modernize healthcare systems, coupled with growing awareness of precision medicine, are driving demand for advanced pathology solutions. In addition, the region's focus on improving cancer diagnosis and treatment is further fueling the adoption of computational pathology technologies, contributing to market expansion.

Key Computational Pathology Company Insights

Key companies are adopting strategies such as mergers and acquisitions, product and service launches, agreements, joint ventures, collaborations, and expansion to strengthen their position in the market.

Recent Developments

• In May 2024, Microsoft collaborated with the University of Washington, and Providence Health aims to address key challenges in implementing AI for cancer diagnostics, leveraging significant scale. The researchers have developed a machine learning model, which Providence describes as one of the most extensive AI training initiatives in real-world whole-slide tissue analysis.

“This transformative work is the result of focused efforts to overcome three major challenges that have stymied previous computational pathology models from widely being applied in the clinical setting: shortage of real-world data, inability to incorporate whole-slide modeling and lack of accessibility,”

-Providence’s chief analytics and research officer 

• In July 2024, Proscia launched an updated version of Concentriq AP. This new release enhances AI's role in advancing pathologists' insights into four of the top five most common cancers globally. Concentriq AP, a cloud-based workflow solution, is designed to deliver significant confidence and efficiency improvements for large global laboratory networks.

“We built the new version of Concentriq AP working closely with our growing customer base to realize our vision for pathology’s precision medicine future. It gives them the features they need to scale their use of AI-enabled pathology and capitalize on the latest innovations that shape our understanding of disease.”

-Proscia’s Senior Vice President of Product

• In May 2021, Quest Diagnostics partnered with Paige.ai for developing AI-driven digital pathology cancer diagnostics. Paige's computational platform uses machine learning to extract diagnostic information from pathology slides, helping pathologists analyze images more quickly and accurately. The collaboration focuses on developing software for diagnosing solid tumors in lung cancer, prostate, and colorectal breast patients and aims to deliver insights to improve cancer diagnosis and make precision medicine more accessible and actionable.

“As the leader in advanced diagnostics, we are excited to actively participate in the creation and use of new technologies that further the mission to make precision medicine clinically accessible, actionable and economical. We are energized about contributing our expertise to Paige’s computational pathology leadership to deliver insights from leading-edge technologies to improve the diagnosis of cancer and other diseases.”

- General Manager, Oncology Franchise, Quest Diagnostics.

Computational Pathology Market Report Scope

Global Computational Pathology Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global computational pathology market report-based on components, application, technology, end-use, and region:

• Component Outlook (Revenue, USD Million, 2018 - 2030)

  • Software

  • Services

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Disease Diagnosis

  • Drug Discovery & Development

  • Academic Research

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Machine Learning (ML)

    • Deep Learning

    • Others

  • Natural Language Processing (NLP) Models

  • Computer Vision

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals and Diagnostic Labs

  • Biotechnology and Pharmaceutical Companies

  • Academic and Research Institutes

  • Other

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait